Transaction Case Studies

US Commercialization Agreement foran Approved Novel Oral Herpes Treatment

Key Activities

  • Developed a commercial assessment including primary market inputs from prescribers and payors.
  • Prepared high impact teaser and management presentation.
  • Conducted an outreach to a large number of leading global and regional companies, both publicly traded and privately held, that are active in the development and commercialization of novel dermatology and primary care products.
  • Led multiple parties through a confidential diligence process resulting in multiple term sheet discussions, exclusive contract negotiations and conclusion of the definitive agreement.

Successful Outcome

  • Competitive process resulted in an exclusive US license of Sitavig® for an up front payment, funding of Phase 4 regulatory commitments, commercial milestones, double-digit royalties, and a supply agreement.
  • Up front payment, near-term economics and deal timing exceeded the client’s expectations due to Locust Walk Partners’ process and negotiations.
  • BioAlliance’s stock price rose ~8% on announcement of the partnership deal, generating ~$17M in market value

View press release »

Back to transactions »



CLIENT: BioAlliance Pharma

PARTNER: Innocutis

US Commercialization Agreement for Sitavig® (acyclovir mucoadhesive tablet)